New drugs for HDL-C disorders: The beginning

My Ngan Duong, Stephen J. Nicholls

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


For more than 20 years there has been increasing interest in the development of novel therapies to raise levels of high-density lipoprotein cholesterol (HDL-C). However, well publicized failures of recent clinical trials of agents that raise HDL-C levels have stimulated considerable controversy with regard to the potential clinical utility of this therapeutic target. A number of classes of agents are currently under investigation with variable effects on HDL quantity and quality. These will be reviewed.

Original languageEnglish
Pages (from-to)2947-2951
Number of pages5
JournalCurrent Medicinal Chemistry
Issue number25
Publication statusPublished or Issued - Aug 2014


  • Atherosclerosis
  • Cardiovascular disease
  • HDL
  • Lipids
  • Risk factors

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry

Cite this